US 11,883,486 B2
Coronavirus vaccine
Susanne Rauch, Tübingen (DE); Hans Wolfgang Große, Tübingen (DE); and Benjamin Petsch, Tübingen (DE)
Assigned to CureVac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on Jun. 1, 2023, as Appl. No. 18/327,882.
Application 18/327,882 is a continuation of application No. 18/179,352, filed on Mar. 6, 2023.
Application 18/179,352 is a continuation of application No. 17/818,699, filed on Aug. 9, 2022, granted, now 11,596,686, issued on Mar. 7, 2023.
Application 17/818,699 is a continuation of application No. 17/526,912, granted, now 11,576,966, issued on Jan. 25, 2023, previously published as PCT/EP2021/052455, filed on Feb. 3, 2021.
Application 17/526,912 is a continuation of application No. 17/276,788.
Claims priority of provisional application 63/129,395, filed on Dec. 22, 2020.
Claims priority of provisional application 63/119,390, filed on Nov. 30, 2020.
Claims priority of provisional application 63/113,159, filed on Nov. 12, 2020.
Claims priority of provisional application 63/112,106, filed on Nov. 10, 2020.
Claims priority of application No. PCT/EP2020/052775 (WO), filed on Feb. 4, 2020; application No. PCT/EP2020/059687 (WO), filed on Apr. 3, 2020; application No. PCT/EP2020/065091 (WO), filed on May 29, 2020; application No. PCT/EP2020/079831 (WO), filed on Oct. 23, 2020; application No. PCT/EP2020/079973 (WO), filed on Oct. 23, 2020; and application No. PCT/EP2020/080713 (WO), filed on Nov. 2, 2020.
Prior Publication US 2023/0302122 A1, Sep. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/215 (2006.01); A61P 31/14 (2006.01); A61K 9/00 (2006.01); A61K 47/26 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/215 (2013.01) [A61K 9/0019 (2013.01); A61K 47/26 (2013.01); A61P 31/14 (2018.01); A61K 2039/53 (2013.01); A61K 2039/6018 (2013.01); A61K 2039/6093 (2013.01)] 50 Claims
 
1. A purified RNA comprising:
(a) a 5′ cap structure;
(b) at least one coding sequence encoding a SARS-CoV-2 spike protein at least 95% identical to SEQ ID NO: 10 that is a pre-fusion stabilized spike protein (S_stab) comprising K986P and V987P stabilizing substitutions and further comprising a D614G amino acid substitution relative to SEQ ID NO: 10; and
(c) a 3′ untranslated region (UTR) comprising at least one poly(A) sequence having 30 to 200 adenosine nucleotides.